MOTS-c Dosage Guide: Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Published / Reviewed July 24, 2026 · Written by Sam Brooks

Educational information only — not medical advice. MOTS-c is not an FDA-approved drug. The doses discussed below are drawn from published research and physician-directed compounded protocols and are provided for education, not as self-administration instructions. Peptide therapy at Beverly Hills Rejuvenation Center is always physician-prescribed and supervised. Do not obtain or inject peptides without a qualified prescriber. If you are a tested athlete, note that MOTS-c is banned by WADA/USADA at all times.

Quick MOTS-c Dosing Summary

In research and physician-supervised settings, MOTS-c is typically dosed at 5–10 mg subcutaneously, given 3–5 times per week, after a 2–4 week titration that starts around 2.5–5 mg. Injections are usually placed in the abdomen in the morning, roughly 30–60 minutes before exercise or fasted cardio, to align with the peptide’s activation of AMPK. A common 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL, so a 5 mg dose equals 1.0 mL (100 units on a U-100 insulin syringe). All of this is provider-directed; MOTS-c is not approved for human treatment.

What Is MOTS-c?

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded not in the cell’s nuclear DNA but within the mitochondrial genome — specifically inside the 12S ribosomal RNA region. It belongs to a small family of mitochondrial-derived peptides (MDPs) that act as signaling molecules between the mitochondria and the rest of the body. It was first characterized by Lee and colleagues in 2015, and interest in it has grown because it appears to behave, in animal models, like a chemical echo of exercise.

How MOTS-c Works in the Body

In preclinical studies, MOTS-c translocates to the cell nucleus under metabolic stress and influences genes tied to antioxidant defense and metabolism. Its most cited action is activation of AMP-activated protein kinase (AMPK) — the cell’s master “energy sensor” that switches on when fuel runs low. AMPK activation promotes glucose uptake, fatty-acid oxidation, and mitochondrial efficiency. Because exercise activates the same pathway, MOTS-c is frequently described as an “exercise-mimetic,” although no clinician should present it as a substitute for physical activity.

Why MOTS-c Is Called an “Exercise Mimetic”

Reynolds and colleagues (2021) showed that MOTS-c is itself induced by exercise and that giving it to aged mice improved running capacity and markers of muscle homeostasis, partly through AMPK and increased GLUT4 glucose-transporter expression in skeletal muscle. In that same body of work, MOTS-c expression rose in human skeletal muscle after acute exercise, and it appeared to interact with exercise to regulate PGC-1α — a master regulator of mitochondrial biogenesis. That is a compelling mechanism — but the treatment findings are animal data. Human efficacy has not been established in large controlled trials, and this guide treats every benefit as “studied for,” not proven.

The Mitochondrial-Derived Peptide Family

MOTS-c is one of several mitochondrial-derived peptides. The best-known is humanin, and the small “SHLP” family (small humanin-like peptides) rounds out the group. What unites them is that they are encoded within mitochondrial DNA rather than the nuclear genome, and they appear to act as retrograde signals — messages sent from the mitochondria outward to influence whole-body metabolism, stress resistance, and aging. This is a relatively young field, which is part of why the clinical literature is still thin: these molecules were only characterized over the last decade or so.

The Genetics Angle: mtDNA Variation

Because MOTS-c is encoded in mitochondrial DNA, researchers have explored whether naturally occurring variants in its coding region correlate with metabolic traits in certain populations. This line of research is intriguing for personalized-medicine discussions but has no bearing on how a dose is currently calculated — dosing is still based on weight, tolerability, and clinical response, not genotype. It is mentioned here only to explain why MOTS-c attracts so much interest in longevity circles.

What MOTS-c Is Studied For

• Metabolic flexibility, insulin sensitivity, and glucose handling
• Physical performance, endurance, and recovery in aged models
• Body-composition support alongside diet and training (often searched as “MOTS-c for weight loss”)
• Cellular/mitochondrial aging research

To be clear about the evidence: the metabolic and longevity findings are largely preclinical or early-stage. MOTS-c is not a weight-loss drug and should not be compared to GLP-1 medications in terms of proven outcomes.

Schedule a Peptide Therapy Consultation to discuss whether a mitochondrial-support protocol is appropriate for you.

Researched Benefits of MOTS-c

Understanding what MOTS-c has actually been shown to do — and in which species — is essential context before any conversation about dose. Below, each area is labeled honestly by evidence strength. Nothing here should be read as a treatment or cure claim.

Metabolic Health and Insulin Sensitivity

The strongest and earliest signal for MOTS-c is metabolic. In the foundational 2015 work, MOTS-c enhanced insulin sensitivity, promoted glucose uptake in muscle, and protected mice against high-fat-diet-induced obesity and insulin resistance. Later work reinforced its role as a regulator of plasma metabolites and insulin action. The mechanism — AMPK activation and improved glucose handling — is biologically plausible in humans, but the outcome data that matter for a person with prediabetes or metabolic syndrome have not yet been produced in large human trials.

Exercise Performance, Endurance, and Recovery

MOTS-c is induced by exercise and, in aged mice, restored a meaningful portion of lost running capacity while improving physical function. This is the basis for its “exercise mimetic” reputation and its popularity among athletes and active adults. It is also precisely why anti-doping authorities prohibit it. For a general patient, the honest framing is that MOTS-c may support the adaptations training already produces — not replace training, and not a guaranteed performance boost.

Aging, Mitochondrial Function, and Longevity Signals

In the aging literature, MOTS-c has been tied to improved mitochondrial function, resistance to metabolic stress, and, in one aged-mouse cohort, a modest extension of median lifespan. Circulating MOTS-c levels also tend to decline with age in humans, which fuels the hypothesis that restoring it could be beneficial. “Fuels the hypothesis” is the operative phrase — a declining biomarker is not proof that supplementation reverses aging, and no human longevity trial has tested this.

Emerging and Speculative Areas

Preclinical papers have touched on bone metabolism, cardiovascular and vascular signaling, and inflammatory pathways. These are early, mechanistic, and largely animal- or cell-based. They may guide future research but do not justify clinical claims today, and a responsible clinic will not market MOTS-c for these uses.

MOTS-c Dosing Protocols Based on Clinical Research

There is no FDA-established human dose for MOTS-c because no pivotal human trial has defined one. The protocols below are extrapolated from animal studies and refined through physician-supervised compounded use. They are presented as reference education, not a prescription.

Standard MOTS-c Dosing Ranges

The most commonly referenced human range is 5–10 mg per subcutaneous injection, 3–5 times per week. Most protocols begin lower — around 2.5–5 mg — and titrate upward over the first few weeks so tolerability can be assessed. Because MOTS-c has a relatively short half-life, it is typically dosed on multiple days per week rather than as a single large weekly dose.

Beginner, Intermediate, and Advanced Tiers

Weight-Based Dosing (Dose per kg)

Some clinicians reference a weight-based figure of roughly 0.05–0.15 mg/kg per dose, extrapolated from animal work using body-surface-area conversion. For an 80 kg (176 lb) adult this equates to about 4–12 mg per dose, which brackets the standard 5–10 mg range. Weight-based math is a starting reference only; it does not override individualized clinical judgment.

MOTS-c Dosing for Metabolic and Body-Composition Goals

People searching “MOTS-c dosage for weight loss” are usually looking for a fat-loss shortcut. That framing is misleading. In studies, MOTS-c improved insulin sensitivity and prevented diet-induced weight gain in mice; it did not produce dramatic caloric-independent fat loss the way GLP-1 receptor agonists do in humans. In practice, providers position MOTS-c as a metabolic-support adjunct to a calorie-appropriate diet and consistent training — not a standalone weight-loss agent. If weight loss is the primary goal, a physician may recommend a different, better-evidenced pathway.

Half-Life and Why Dosing Frequency Matters

MOTS-c has a relatively short circulating half-life, which is the practical reason it is dosed several times per week rather than as a single large weekly bolus. Frequent, smaller doses aim to keep the AMPK-related signal periodically engaged without loading the body with an unnecessarily large amount at once. This is also why “just take more, less often” is not a shortcut — the schedule is built around the peptide’s pharmacokinetics, not just the weekly total. Your provider sets frequency based on goals, tolerability, and the specific protocol.

The Case for Starting Low and Titrating

Titration — beginning near the low end and increasing only if a dose is well tolerated — is standard for good reason. It lets both patient and clinician observe how the individual responds before committing to a higher exposure, reduces the chance and severity of side effects, and creates a clean baseline for judging benefit. With an experimental compound and no fixed FDA dose, conservative titration is the responsible default rather than jumping straight to the top of the range.

Clinical Trial Data and Evidence Limits

Human data remain early. A first-in-human Phase I safety evaluation reported no serious adverse events with subcutaneous MOTS-c at doses up to approximately 10 mg, and pharmacokinetics consistent with intermittent dosing. That is reassuring for short-term tolerability but does not establish efficacy, optimal dose, or long-term safety. The bulk of the mechanistic and outcome data — insulin sensitivity, endurance, muscle homeostasis, lifespan signals — comes from rodent studies. Any honest guide must say so.

How to Reconstitute MOTS-c

MOTS-c is supplied as a lyophilized (freeze-dried) white powder that must be reconstituted with bacteriostatic water before use. In a clinical setting this is handled by the compounding pharmacy or trained staff; the walkthrough below explains the process for education and is not an instruction to self-compound gray-market vials.

Bacteriostatic vs. Sterile Water: Why It Matters

Reconstitution should use bacteriostatic water — sterile water that contains 0.9% benzyl alcohol as a preservative. The preservative inhibits microbial growth, which is what allows a reconstituted, multi-dose vial to be used over roughly four weeks. Plain sterile water contains no preservative and is intended for single use; a vial mixed with it should be used immediately and discarded, making it impractical for a multi-dose peptide. Benzyl alcohol is also why bacteriostatic water is generally avoided in neonates and, out of caution, in pregnancy — another reason MOTS-c belongs in supervised care.

Step-by-Step Reconstitution

1. Let the sealed vial and bacteriostatic water reach room temperature. Wash hands and work on a clean surface.
2. Wipe both rubber stoppers (peptide vial and bacteriostatic water vial) with fresh alcohol swabs.
3. Draw the chosen volume of bacteriostatic water (for example, 2 mL) into a sterile syringe.
4. Insert the needle at an angle and let the water run slowly down the inside wall of the vial — never blast it directly onto the powder.
5. Swirl gently; do not shake. Peptides are fragile, and vigorous shaking can denature them and cause foaming. Allow a minute for the powder to dissolve into a clear solution.
6. Discard any solution that is cloudy or contains visible particulate. Label the vial with concentration and date.
7. Store reconstituted MOTS-c refrigerated at 2–8 °C, protected from light. Use within roughly 28 days.

Choosing Your Bacteriostatic Water Volume

The volume of bacteriostatic water you add determines the concentration (mg/mL) and therefore how many syringe units equal a given dose. More water = more dilute = larger, easier-to-measure volumes but a fuller syringe. Less water = more concentrated = smaller volumes. A clean, low-math standard is a 10 mg vial + 2 mL water = 5 mg/mL, where 1 unit on a U-100 insulin syringe equals 0.05 mg.

MOTS-c Reconstitution Calculator: 5 mg and 10 mg Vials

The tables below assume a standard U-100 insulin syringe, where 100 units = 1.0 mL. “Units” refers to the mark on that syringe.

*A single U-100 insulin syringe holds 100 units (1 mL). Doses above 100 units require two draws or a larger syringe. This is one reason a concentration that keeps your dose at or under 100 units per injection is preferred.

Dosing Calculation Examples (Syringe Math)

• Example 1 — 5 mg dose from a 10 mg vial + 2 mL (5 mg/mL): 5 mg ÷ 5 mg/mL = 1.0 mL = 100 units (a full standard insulin syringe).
• Example 2 — 5 mg dose from a 10 mg vial + 1 mL (10 mg/mL): 5 mg ÷ 10 mg/mL = 0.5 mL = 50 units (half a syringe).
• Example 3 — 2.5 mg titration dose from a 10 mg vial + 2 mL (5 mg/mL): 2.5 mg ÷ 5 mg/mL = 0.5 mL = 50 units.
• Example 4 — 7.5 mg dose from a 10 mg vial + 1 mL (10 mg/mL): 7.5 mg ÷ 10 mg/mL = 0.75 mL = 75 units.

The general formula: Units = (desired mg ÷ concentration in mg/mL) × 100. Your prescribing clinician should confirm every calculation before any injection.

Common Reconstitution Mistakes to Avoid

• Shaking the vial. The single most common error. Shaking introduces shear stress and foaming that can degrade the peptide. Swirl gently only.
• Spraying water onto the powder. Direct, forceful streams can damage the delicate peptide; aim for the vial wall.
• Confusing “units” with “milligrams.” Units are a volume mark on the syringe, not a mass. The conversion depends entirely on your concentration.
• Ignoring concentration when the vial size changes. A dose that is 50 units at 10 mg/mL becomes 100 units at 5 mg/mL. Re-check the math every time a new vial is mixed.
• Overfilling the syringe. If a single dose exceeds 100 units, choose a more concentrated mix so it fits in one draw and reduces error.

MOTS-c Administration Guide

MOTS-c is given by subcutaneous injection — into the fat layer just beneath the skin, not into muscle or vein. The technique mirrors that of insulin or other subcutaneous peptides and is taught by the clinical team before any patient administers a dose at home.

Injection Site Selection

• Abdomen — the most common site; stay at least 2 inches (about 5 cm) away from the navel.
• Outer thigh — the front/outer portion.
• Back of the upper arm — where enough subcutaneous fat is present.
• Upper/outer buttock — an option for rotation.

Rotate sites with each injection to reduce irritation and lipohypertrophy (fatty lumps). Do not inject into skin that is bruised, tender, scarred, or inflamed.

Subcutaneous Injection Technique

1. Wash hands; swab the chosen site with alcohol and let it dry.
2. Draw the prescribed number of units; tap out air bubbles.
3. Pinch a fold of skin. Insert the short insulin needle at a 45–90° angle depending on body-fat thickness.
4. Depress the plunger slowly and steadily to deliver the full dose.
5. Withdraw the needle, release the pinch, and apply light pressure with a clean swab. Do not rub vigorously.
6. Dispose of the needle in a proper sharps container — never reuse needles.

Reducing Injection Discomfort

Subcutaneous injections with a fine insulin needle are generally low-pain, and a few habits make them easier still: let the alcohol dry completely before inserting the needle (injecting into wet alcohol stings), use a brand-new sharp needle each time, insert with a quick, confident motion rather than a slow push, keep the reconstituted solution from being ice-cold at the moment of injection, and relax the muscle/skin around the site. If a particular site is consistently tender, rotate away from it. Persistent, worsening, or infected-looking sites should always be reviewed by the care team rather than pushed through.

Needle and Syringe Selection

Subcutaneous MOTS-c is typically drawn and injected with a small-gauge, short insulin needle — commonly around 29–31 gauge and 5/16 to 1/2 inch (8–13 mm) long. A U-100 insulin syringe is standard because its unit markings make small-volume dosing precise. A new sterile needle is used for every injection; needles dull quickly and reuse increases pain, infection risk, and tissue trauma. All sharps go into an approved container, never household trash.

Storage and Handling After Reconstitution

Keep reconstituted MOTS-c refrigerated (2–8 °C) and shielded from light and heat. Lyophilized (un-reconstituted) powder is more stable and is often kept frozen for long-term storage per pharmacy guidance. Once mixed, plan to use within about 28 days, and discard early if the solution turns cloudy, discolored, or shows particulate. Avoid leaving vials at room temperature for extended periods, and do not freeze reconstituted solution unless specifically directed by the pharmacy. When traveling, transport in an insulated cooler with a cold pack, keeping the vial cold but not frozen.

Optimal Timing for MOTS-c Administration

Timing is one of the more distinctive parts of a MOTS-c protocol because the peptide’s mechanism is tied to the body’s energy state.

Why Morning and Pre-Exercise Timing Is Preferred

MOTS-c works through AMPK — a pathway that is most active when cellular energy is low, such as during fasting and exercise. Many protocols therefore place the injection in the morning, roughly 30–60 minutes before training or fasted cardio, on the theory that dosing into an already energy-sensing state may complement the peptide’s action and support substrate utilization during the session. This is a mechanistic rationale, not a proven performance claim.

Fasted vs. Fed Dosing

Because AMPK signaling is heightened in the fasted state, MOTS-c is commonly taken before eating in the morning. There is no robust human trial establishing that fasted dosing outperforms fed dosing; it is a reasonable, mechanism-based convention rather than a hard rule.

Consistency and Spacing of Doses

For multi-day-per-week schedules, spacing doses evenly (for example, Monday/Wednesday/Friday, or five weekday mornings) helps maintain steady exposure. Consistency of time-of-day and routine matters more than chasing a perfect window.

Timing on Rest Days

On non-training days within a dosing week, MOTS-c is usually still taken in the morning to preserve routine and keep dosing intervals even. Some protocols simply skip dosing on rest days, especially when the schedule is built around workouts. Which approach fits depends on the individual protocol and should be set with a provider rather than improvised.

A Note on Circadian Biology

Because MOTS-c interacts with energy-sensing pathways that themselves follow a daily rhythm, morning administration also aligns with the body’s natural metabolic peak earlier in the day. This is a soft rationale layered on top of the pre-exercise logic; it is not a reason to obsess over exact minutes. The practical takeaway is simple: pick a consistent morning time and keep it.

MOTS-c Cycle Length and Protocol Duration

MOTS-c is generally used in defined cycles rather than open-endedly, both to reassess response and because long-term human safety data do not exist.

Typical Cycle Structures

• Continuous block: 4–8 weeks of 3–5×/week dosing, followed by a break and reassessment.
• Pulsed 10/10: 10 consecutive days on (often 10 mg daily), then 10 days off — a frequently cited MOTS-c pattern.
• 5-on / 2-off weekly: five weekday doses with weekends off, run for several weeks.

How Long Until Effects Appear

In practice, patients and providers often look for changes over a 4–8 week window — energy, workout capacity, recovery, and metabolic lab markers. Individual response varies, and subjective effects are not a substitute for objective monitoring. Some report subtle changes within the first couple of weeks; others notice little without concurrent training and nutrition.

Why MOTS-c Is Cycled Rather Than Used Continuously

There are two reasons protocols favor cycling. First, receptor and signaling systems can adapt to constant stimulation; intermittent exposure is a hedge against diminishing returns, though this has not been formally quantified for MOTS-c in humans. Second, and more importantly, the absence of long-term human safety data makes open-ended use hard to justify. Defined cycles with reassessment keep the risk-to-benefit conversation active rather than letting a protocol run indefinitely on autopilot.

Breaks and Reassessment

Building in off-cycle periods gives a clinician the chance to review labs, symptoms, and goals before continuing. If there is no measurable benefit after a fair trial, continuing is rarely justified given the experimental status of the peptide. Off-cycle intervals also let the injection sites recover and give the patient a clear point to decide whether the therapy is worth continuing at all.

MOTS-c Safety Profile and Potential Side Effects

Early human safety data are limited but so far reassuring for short-term use: a Phase I evaluation reported no serious adverse events at subcutaneous doses up to about 10 mg. That said, the long-term safety of MOTS-c in humans is genuinely unknown, and reported side effects come largely from clinical use and self-report rather than large trials.

Common and Mild Side Effects

• Injection-site reactions — redness, itching, swelling, or a small bruise
• Transient fatigue or lightheadedness, sometimes linked to fasted dosing
• Mild flushing or warmth
• Headache
• Changes in appetite
• Because MOTS-c can influence glucose handling, theoretically low blood sugar (hypoglycemia) is a consideration — especially if fasted or on glucose-lowering medication.

Contraindications and Cautions

• Pregnancy and breastfeeding — avoid; no safety data.
• Active cancer or history of certain cancers — requires oncology input; metabolic/AMPK modulation is complex.
• Diabetes or use of glucose-lowering drugs — heightened hypoglycemia risk; requires close monitoring.
• Known hypersensitivity to the peptide or excipients.
• Anyone unable to obtain a physician-supervised, pharmacy-sourced product should not use MOTS-c at all.

Drug and Supplement Interactions

The most clinically relevant interaction concern is with glucose-lowering agents (insulin, sulfonylureas, GLP-1 medications, metformin), where additive effects on blood sugar are plausible. Other AMPK-active compounds and stimulants should be reviewed with a prescriber. Because MOTS-c is not an approved drug, formal interaction studies are lacking — which is exactly why a supervising physician and a full medication list matter.

When to Seek Medical Attention

Most reported effects are mild and self-limiting, but certain signs warrant prompt contact with a clinician or urgent care: symptoms of a significant allergic reaction (widespread rash, swelling of the face/lips/tongue, difficulty breathing), signs of hypoglycemia that do not resolve with food (shakiness, confusion, sweating, palpitations), a spreading, painful, or pus-producing injection-site infection, or any severe or persistent symptom. Because MOTS-c is not an approved drug, patients should err on the side of reporting anything unusual to the prescribing team.

Managing Injection-Site Reactions

Minor redness, itching, or a small bruise is common and usually resolves within a day or two. Rotating sites, allowing alcohol to dry fully before injecting, using a fresh needle each time, and injecting slowly all reduce local reactions. Persistent lumps (lipohypertrophy) or repeated irritation at a site should prompt a change in technique or location and a conversation with the provider.

The Gray-Market Sourcing Risk

A large share of real-world MOTS-c risk has nothing to do with the peptide itself: it comes from unregulated “research-only” vials sold online with no guarantee of identity, purity, dose accuracy, or sterility. Contaminants, endotoxins, and mislabeled concentrations are documented problems in the gray market. BHRC’s position is unambiguous — MOTS-c should only ever be used as a physician-prescribed, pharmacy-compounded product under supervision.

Schedule a Peptide Therapy Consultation to review your health history and medications before considering any peptide protocol.

Combining MOTS-c with Other Peptides and Therapies

MOTS-c is frequently discussed alongside other peptides in “stacks.” Stacking multiplies both potential benefit and potential risk, and should only be designed by a clinician. The comparison matrix below outlines how MOTS-c differs from peptides it is commonly paired with — it is educational, not a recommendation to combine them.

MOTS-c vs. Commonly Paired Peptides

MOTS-c and SS-31: A Mitochondrial Pairing

SS-31 (elamipretide) is sometimes discussed with MOTS-c because the two act on mitochondria through different mechanisms — MOTS-c via AMPK signaling, SS-31 by stabilizing the inner mitochondrial membrane. In theory they are complementary, but both are investigational, human stack data are absent, and combining two experimental peptides compounds uncertainty. This is squarely a physician-only decision.

MOTS-c and CJC-1295 / Ipamorelin

Because MOTS-c targets metabolism while CJC-1295/Ipamorelin works on the growth-hormone axis for recovery and body composition, some protocols pair them. If you are exploring a recovery-and-metabolism combination, our clinicians can explain the trade-offs — see our CJC-1295/Ipamorelin therapy page. Any stack requires supervision and is never appropriate for tested athletes given anti-doping rules.

MOTS-c and Tesamorelin or AOD-9604 for Body Composition

Patients whose primary goal is body composition sometimes ask about pairing MOTS-c with growth-hormone-axis peptides like Tesamorelin (FDA-approved for HIV-associated visceral fat) or the GH fragment AOD-9604. The logic is that MOTS-c addresses metabolic signaling while the others target fat mobilization or the GH axis. As with any stack, this multiplies variables and side-effect potential, and there is no human trial validating the combination. See our Tesamorelin and AOD-9604 pages, and let a clinician decide whether one agent, or none, is the better fit.

Stacking Cautions and Additive Risk

Two principles govern responsible stacking. First, introduce one variable at a time — starting several peptides simultaneously makes it impossible to attribute a benefit or a side effect. Second, remember that each added compound carries its own contraindications and interaction profile; risks add up rather than cancel out. Athletes must also note that stacking MOTS-c with other prohibited substances compounds anti-doping exposure. None of the combinations discussed here are recommendations — they are educational context for a clinician-led decision.

MOTS-c Alongside Diet, Training, and Sleep

The most defensible “stack” for MOTS-c is not another peptide at all — it is the fundamentals. Since MOTS-c mirrors exercise signaling, its rationale is strongest as an adjunct to consistent resistance and aerobic training, adequate protein, sleep, and a sensible caloric plan. Peptides layered on a poor foundation rarely deliver.

Who Should Consider MOTS-c Therapy?

MOTS-c is not for everyone, and at BHRC candidacy is determined by a physician after review of history, goals, and labs.

Potential Candidates

• Adults focused on metabolic health, insulin sensitivity, and body composition who have optimized diet and training
• Active individuals seeking mitochondrial and recovery support within a supervised program
• Patients interested in longevity-oriented, closely monitored protocols who understand the evidence is early

Who Should Not Use MOTS-c

• Anyone pregnant, trying to conceive, or breastfeeding
• Tested athletes bound by WADA/USADA rules (MOTS-c is banned at all times)
• People with active cancer, uncontrolled diabetes, or unmanaged serious illness without specialist clearance
• Anyone unwilling or unable to use a physician-prescribed, pharmacy-sourced product

MOTS-c Compared to Other Metabolic Approaches

It helps to place MOTS-c in context. For patients whose main goal is significant weight loss, GLP-1 and dual-agonist medications have far more robust human evidence and would usually be the first conversation. For those focused on visceral fat, Tesamorelin has an actual FDA-approved indication in a specific population. MOTS-c occupies a different niche: a mechanistically interesting, exercise-adjacent metabolic-support option with early evidence, best suited to motivated patients who already train and eat well and who understand they are opting into something experimental. Naming that trade-off honestly is part of good candidacy assessment — sometimes the right answer is a better-established therapy, or lifestyle work first.

The Consultation and Candidacy Process

A BHRC evaluation includes medical history, current medications, goals, and baseline labs. Only after that review does a provider determine whether MOTS-c — or a different, better-suited therapy — makes sense, and at what dose and schedule. The consultation is also where realistic expectations, monitoring cadence, and stop criteria are set, so that the decision to start (or not) is made with full information rather than marketing hype.

Monitoring Progress and Adjusting Protocols

Because MOTS-c is experimental, structured monitoring is what separates responsible use from guesswork.

Baseline and Follow-Up Labs

• Fasting glucose and HbA1c; fasting insulin / HOMA-IR where indicated
• Lipid panel
• Comprehensive metabolic panel (liver and kidney function)
• Body-composition measures (weight, waist, and where available DEXA or bioimpedance)

Tracking Subjective and Performance Markers

Alongside labs, patients often log energy, workout performance and recovery, sleep quality, and appetite. These subjective markers help contextualize lab trends but should not drive dosing on their own.

When and How to Adjust the Dose

Dose changes are made by the prescriber based on tolerability and objective response — for example, titrating upward only if a lower dose is well tolerated, or discontinuing if there is no measurable benefit after a fair cycle. Self-escalating dose or frequency is discouraged; more is not reliably better and increases the odds of side effects.

Setting Realistic Expectations

MOTS-c is not a dramatic, felt-instantly compound for most people. Where benefits appear, they tend to be incremental and to layer on top of good training and nutrition rather than substitute for them. Framing expectations honestly at the outset — a defined trial, clear metrics, and a willingness to stop if the data do not support continuing — is part of using an experimental peptide responsibly. A clinic that promises transformation is a red flag.

Is MOTS-c FDA-Approved? Legal & Regulatory Status (2026)

As of July 24, 2026, MOTS-c is not approved by the U.S. Food and Drug Administration for any indication. It has not completed the large controlled human trials required for approval, and it is not sold as an approved medication.

FDA and Compounding Status

MOTS-c is used in humans only through physician prescription and pharmacy compounding, or in research settings. It is not an over-the-counter supplement, and the “research use only” vials marketed online are not intended or tested for human injection. Presenting MOTS-c as “approved” or as a proven treatment would be inaccurate — this guide does not do so.

WADA / USADA Status for Athletes

MOTS-c is prohibited at all times under the World Anti-Doping Agency Prohibited List as a metabolic modulator — specifically within the class covering activators of AMP-activated protein kinase (AMPK). The U.S. Anti-Doping Agency has issued an athlete advisory confirming this and noting that, because MOTS-c has no approved therapeutic use, it is not eligible for a Therapeutic Use Exemption. A metabolic-modulator finding can carry a multi-year sanction. Any athlete subject to testing should treat MOTS-c as strictly off-limits.

Compounded Peptides and the Regulatory Landscape

Access to certain compounded peptides has tightened in recent years as the FDA has reviewed the category and moved some substances off the list eligible for pharmacy compounding. The regulatory picture can shift, which is another reason to work through a clinic that tracks current rules and sources from licensed pharmacies rather than relying on the internet. What is available and appropriate is a moving target that a qualified prescriber is positioned to navigate; a research-vendor website is not.

“Research Use Only” Labeling Explained

Vials sold online are almost always labeled “for research use only” or “not for human consumption.” That labeling is not a wink-and-nod formality — it reflects that the product has not been manufactured, tested, or released to the standards required for human injection. Purity, sterility, endotoxin levels, and even the actual peptide identity are unverified. Treating a research-labeled vial as a medication is exactly the behavior this guide advises against.

Buying Peptides Online: The Legal and Safety Gray Zone

The unregulated online market exists in a legal gray zone and carries real safety hazards — unverified purity, inaccurate dosing, and contamination. BHRC does not sell or endorse research-vendor peptides. The responsible path is a supervised clinical program where sourcing, dosing, and monitoring are controlled.

Conclusion

MOTS-c is one of the more scientifically interesting peptides in the longevity and metabolic space: a mitochondrial-derived signal that, in animal models, activates AMPK and mimics aspects of exercise. In physician-supervised practice it is typically dosed at 5–10 mg subcutaneously, 3–5 times per week, after a careful titration, timed to the morning and pre-exercise, and run in defined cycles with lab monitoring. But the honest bottom line is that most efficacy evidence remains preclinical or early-stage, long-term human safety is unknown, MOTS-c is not FDA-approved, and it is banned for tested athletes. That combination is exactly why MOTS-c belongs inside a supervised medical program — not a gray-market self-experiment. Used correctly, it is one tool among several, chosen only when it genuinely fits a patient’s goals, labs, and risk tolerance, and dosed conservatively with real monitoring. If you want to explore whether a mitochondrial-support protocol fits your goals, our clinical team can help you weigh the evidence honestly and compare it against better-established options.

Schedule a Peptide Therapy Consultation with Beverly Hills Rejuvenation Center, or learn more on our MOTS-c therapy page.

Frequently Asked Questions About MOTS-c Dosing

What is the standard MOTS-c dosage?

In research and physician-supervised settings, MOTS-c is commonly dosed at 5–10 mg subcutaneously, 3–5 times per week, after a 2–4 week titration starting near 2.5–5 mg. There is no FDA-established human dose, so these ranges are extrapolated from studies and clinical use and must be individualized by a prescriber.

How do I reconstitute a 10 mg MOTS-c vial?

Add bacteriostatic water down the inside wall of the vial and swirl gently — never shake. Adding 2 mL to a 10 mg vial gives 5 mg/mL, so a 5 mg dose equals 1.0 mL (100 units on a U-100 insulin syringe). Adding 1 mL gives 10 mg/mL, so a 5 mg dose equals 0.5 mL (50 units). Refrigerate and use within about 28 days.

What is the MOTS-c dose per kg of body weight?

Some clinicians reference roughly 0.05–0.15 mg/kg per dose, extrapolated from animal studies. For an 80 kg adult that is about 4–12 mg, which brackets the standard 5–10 mg range. Weight-based math is only a starting reference and does not replace individualized clinical judgment.

When should I take MOTS-c — what is the best timing?

Most protocols place the injection in the morning, about 30–60 minutes before exercise or fasted cardio. The rationale is mechanistic: MOTS-c activates AMPK, a pathway already heightened during fasting and exercise. This is a reasonable convention, not a proven performance requirement.

How long should a MOTS-c cycle last?

Common structures include a 4–8 week block of 3–5×/week dosing, or a pulsed “10 days on / 10 days off” pattern, followed by a break and reassessment. Because long-term human safety data are lacking, MOTS-c is generally cycled rather than used continuously.

Is MOTS-c good for weight loss?

MOTS-c improved insulin sensitivity and prevented diet-induced weight gain in mice, but it is not a proven human weight-loss drug and is not comparable to GLP-1 medications. Providers position it as a metabolic-support adjunct to diet and training, not a standalone fat-loss agent.

What are the side effects of MOTS-c?

Reported effects are usually mild: injection-site redness or bruising, transient fatigue or lightheadedness, mild flushing, and headache. Because MOTS-c affects glucose handling, hypoglycemia is a theoretical concern, especially when fasted or on glucose-lowering medication. Long-term human safety is unknown.

Can MOTS-c be stacked with other peptides like SS-31 or CJC-1295/Ipamorelin?

It is sometimes paired with SS-31 (a different mitochondrial mechanism) or with CJC-1295/Ipamorelin (growth-hormone axis) for complementary goals. However, combining experimental peptides compounds uncertainty and risk, human stack data are lacking, and any stack must be designed and supervised by a physician.

Is MOTS-c FDA-approved or legal?

As of 2026, MOTS-c is not FDA-approved for any use. It is used in humans only via physician prescription and pharmacy compounding, or in research. Online “research-only” vials are not intended for human injection, and MOTS-c is banned at all times for tested athletes under WADA/USADA rules.

Do I need a prescription and medical supervision for MOTS-c?

Yes. Given its experimental status, glucose-related effects, interaction considerations, and the safety hazards of gray-market vials, MOTS-c should only be used under a qualified prescriber who controls sourcing, dosing, and monitoring. BHRC provides physician-supervised peptide programs and does not endorse self-sourced peptides.

Related Resources / Related Blogs from BHRC

• MOTS-c Peptide Therapy at BHRC — our clinical MOTS-c program.
• CJC-1295 / Ipamorelin Therapy — growth-hormone-axis support and recovery.
• Tesamorelin Therapy — targeted visceral-fat protocols.
• AOD-9604 Therapy — body-composition-focused peptide.
• Schedule a Peptide Therapy Consultation — start with a physician evaluation.

References

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009. Link
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. PMCID: PMC7817689. Link
3. Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports. 2019;7(13):e14171. doi:10.14814/phy2.14171. Link
4. Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism (review context on MOTS-c and muscle/fat metabolism). PMCID: PMC5116416. Link
5. Kim KH, Son JM, Benayoun BA, Lee C. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes & Metabolism Journal. Link
6. U.S. Anti-Doping Agency (USADA). What is the MOTS-c peptide? Athlete advisory. Link
7. World Anti-Doping Agency (WADA). The Prohibited List — S4 Hormone and Metabolic Modulators (AMPK activators). Link

Author and Medical Reviewer

Author — Sam Brooks. Sam is a health content writer at Beverly Hills Rejuvenation Center specializing in evidence-based peptide, hormone, and regenerative-medicine education.

About the medical review: This guide was reviewed by the clinical team at Beverly Hills Rejuvenation Center — board-certified physicians and licensed medical providers who oversee BHRC’s medical protocols and review its clinical education for accuracy, safety, and compliance. Reviewed July 24, 2026. This content is educational and does not replace an individual medical evaluation; peptide therapy at BHRC is physician-supervised.